Welcome to our dedicated page for NeuroBo Pharmaceuticals SEC filings (Ticker: NRBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NeuroBo Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NeuroBo Pharmaceuticals's regulatory disclosures and financial reporting.
MetaVia Inc. Reporting persons Armistice Capital, LLC and Steven Boyd disclose beneficial ownership of 1,270,887 shares of MetaVia common stock, representing 4.99% of the class. Armistice Capital is the investment manager to Armistice Capital Master Fund Ltd., the direct holder, and exercises shared voting and dispositive power over the shares reported. Mr. Boyd, as managing member of Armistice Capital, is also reported as having shared voting and dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Woodworth Marshall H, listed as Chief Financial Officer, reported a Form 4 for MetaVia Inc. (MTVA) showing a transaction dated 08/12/2025. The filing records a transaction code G and shows acquisition of 14,200 shares at a price of $0, bringing his beneficial ownership to 30,079 shares. The Form 4 was executed by a power of attorney on 08/13/2025 and includes Exhibit 24 (Power of Attorney).
MetaVia Inc. Form 8-K — Regulation FD disclosure (Aug 6, 2025)
MetaVia furnished a press release announcing an extension of the 48 mg multiple ascending dose (MAD) cohort in the Phase 1 clinical trial of DA-1726 from 4 weeks to 8 weeks and reporting that a fifth weekly dose was administered to the first patient. DA-1726 is described as a novel dual oxyntomodulin (OXM) analog agonist acting at GLP1R and GCGR for obesity treatment.
- Date: August 6, 2025
- Action: Cohort duration extended to 8 weeks (from 4 weeks)
- Dosing update: Fifth weekly dose given to first patient
- Exhibit: Press release furnished as Exhibit 99.1 (information furnished, not filed)